Diagnosis of many life-threatening illnesses, including acute pulmonary embolism, aortic dissection, and ischaemic bowel disease, requires confirmatory radiological imaging with radiocontrast. It is well established that radiocontrast can induce acute kidney injury, especially in patients with pre-existing renal impairment. The decision to proceed with a radiological study with radiocontrast to confirm or exclude a life-threatening, but potentially reversible, illness in patients with renal impairment is difficult. Theoretically, a radiocontrast study will be justifiable provided its benefits outweigh its harms. Using published prognostic data of contrast-induced nephropathy (CIN), this decision analysis aimed to assess whether a certain threshold of pre-test probability of a life-threatening illness is needed before a radiocontrast study can be justified for patients with different levels of renal impairment. In critically ill patients presenting with a life-threatening illness with hypotension requiring vasopressors or inotropes, the risk of CIN (defined by an increment in plasma creatinine of 40 µmol/l) and the associated attributable mortality after using 50 to 100 ml of radiocontrast was about 30% and 4%, respectively, for patients with baseline plasma creatinine concentrations <400 µmol/l. The risk of CIN and its associated attributable mortality increased substantially and exceeded 80% and 10%, respectively, if patients also had diabetes mellitus and their baseline plasma creatinine concentrations were >400 µmol/l. In the latter high-risk patients, using a radiocontrast study to diagnose or exclude a life-threatening illness could only be justified if the life-threatening illness was readily treatable and the pre-test probability of having such disease was greater than 15%-20%.
Introduction
Radiological imaging is increasingly used to assist clinical management of critically ill patients. For patients presenting with non-specific symptoms such as chest or abdominal pain, computed tomography (CT) angiography is often needed to confirm or exclude a life-threatening illness such as acute pulmonary embolism, aortic dissection, or ischaemic bowel. In addition to a small risk of anaphylaxis, use of radiocontrast can also induce acute kidney injury or contrast-induced nephropathy (CIN), especially in patients with pre-existing renal impairment. Although most patients who develop CIN will not require dialysis and will recover without permanent complications, there is increasing evidence to suggest that CIN can induce long-term renal damage and mortality in high-risk patients. In the study by Mehran et al, the risk of requiring dialysis for CIN and the one-year mortality were 13% and 33% for those with multiple risk factors for CIN compared to only <0.5% and 2% for those with the lowest risk of developing CIN, respectively 1 . The clinical significance of CIN was further confirmed by a recent study which showed that nearly one-third of the in-hospital mortality after percutaneous coronary intervention was attributable to CIN, and that one death could be potentially prevented by preventing nine cases of CIN 2 .
The decision to proceed with a radiological study with a radiocontrast agent to confirm or exclude a life-threatening, but potentially reversible or treatable, illness in patients with renal impairment is difficult. Theoretically, a radiocontrast study will be justifiable provided its benefits outweigh its harms. In practice, to balance the benefit and risk of a radiocontrast study for critically ill patients is challenging. Firstly, in critically ill patients presenting with symptoms of a life-threatening illness, opportunities to use prophylactic measures against CIN, including aggressive intravenous hydration, are limited [3] [4] [5] [6] . Secondly, although renal impairment is the most established and important risk factor for CIN, other risk factors such as hypotension, diabetes mellitus, anaemia, and older age are also common in the critically ill 1, 7 . Furthermore, the risk of CIN can vary significantly between different types of radiocontrast studies, with a strong interaction between the dose of contrast and baseline renal function in inducing CIN and its associated morbidities 3, [8] [9] [10] [11] . It has been estimated that the risk of CIN could be doubled when the volume of contrast (in ml) to the estimated creatinine clearance (eCrCl in ml/minute) ratio is over 2.5-3.
Although balancing the benefits and risks of an emergency radiocontrast study for critically ill patients is challenging, it is possible to determine when the risk of a radiocontrast study outweighs the benefit of a radiocontrast study by comparing the attributable mortality of CIN with the pretest (or pre-radiocontrast study) probability of the treatable life-threatening illness. Patients with different levels of renal impairment would require different pre-test probabilities to justify the associated mortality risk attributed to the radiocontrast study. In this decision analysis study, we aimed to assess whether a certain pre-test probability of a lifethreatening illness is needed for most critically ill patients to justify the risk of CIN from an emergency diagnostic radiocontrast study.
Methods
This decision analysis utilised published data on CIN in the literature. In estimating the risk of CIN and its associated mortality, the following working assumptions were used.
The Cockcroft-Gault formula was used to estimate the eCrCl, assuming the patient was a 60-year-old male and the body weight was 80 kg 12 . An eCrCl <20, 20-40, 40-60, >60 ml/minute corresponded to plasma creatinine concentrations <130 µmol/l, 130-200 µmol/l, 200-400 µmol/l and >400 µmol/l, respectively.
The CIN risk calculator, developed originally by Mehran et al using patients who underwent percutaneous coronary intervention and recently revalidated, was used to estimate the risk of CIN in patients with different characteristics 1, 7 .
The average in-hospital mortality attributed to CIN was assumed to be 11.1% 2 . The very high one-year mortality associated with CIN (33.3%) reported by Mehran et al was not used in this study because this figure was likely inflated by the effect of residual confounding due to the associations between similar prognostic factors for both long-term survival and CIN (e.g. older age, congestive heart failure, diabetes mellitus) 1 . The haematocrit of critically ill patients who required an urgent radiocontrast study was assumed to be relatively low (<38%), which increased the risk score for CIN by three points according to the CIN risk calculator 1 .
For most emergency radiocontrast studies (e.g. CT pulmonary angiography, CT aortography, CT abdominal angiography), between 50 and 100 ml of radiocontrast would be needed. For patients with severe pre-existing risk impairment (eCrCl <20 ml/minute), the estimated risk of CIN would be twice as estimated by the CIN risk calculator because the volume of contrast needed (in ml) would exceed 2.5-3.0 times the value of eCrCl (in ml/minute) 3, [8] [9] [10] [11] .
Because most prophylactic measures against CIN could not be administered well in advance before an emergency radiocontrast study 4, 5 , any prophylactic measures initiated after the administration of intravenous radiocontrast would confer minimal or no measurable benefits on risk of CIN.
Because hypotension (systolic blood pressure <80 mmHg for at least one hour requiring vasopressors or inotropes within 24 hours of radiocontrast study) and diabetes mellitus were important risk factors for CIN and its associated mortality 1 , the decision analyses were stratified according to these two important risk factors.
In a series of 986 consecutive patients who had symptoms consistent of acute pulmonary embolism who required urgent CT pulmonary angiography to diagnose or exclude acute pulmonary embolism over a four-month period in five hospitals in Western Australia 13 , the pre-test probability of acute pulmonary embolism was 15.1%. Although pre-test probability of a life-threatening illness would vary between patients with different symptoms in different types of lifethreatening illnesses, a prevalence of an undiagnosed lifethreating illness >20% would suggest that a gold standard diagnostic test is required to exclude the life-threatening illness 14 . In the current study, a pre-test probability of >10% of having a life-threatening disease was assumed to be common in most critically ill patients who required a radiocontrast study to exclude such a disease and would be used to compare with the attributable mortality rate of CIN for patients with different levels of baseline renal function.
Results
For patients without hypotension and diabetes mellitus, the estimated risk of CIN varied between 8% and 26% and the associated attributable mortality rate was between 0.9% and 2.9%, depending on the baseline renal function ( Figures  1 and 2 ). For patients with both hypotension and diabetes mellitus, the estimated risk of CIN and in-hospital mortality was 30%-100% and 3.3%-11%, respectively (Figures 3 and  4) ; with a steep increase in both risk of CIN and its associated mortality when eCrCl was <20 ml/minute (or plasma creatinine concentration >400 µmol/l). With the exception of the subgroup of patients with severe renal impairment (eCrCl <20 ml/minute) who also had hypotension and diabetes mellitus (11%), the attributable mortality risk associated with CIN was lower than the pre-test probability of a lifethreatening illness in critically ill patients presenting with symptoms consistent with such disease (>10%) 13 .
Discussion
This decision analysis showed that for most critically ill patients with mild to moderate renal impairment (or plasma creatinine concentration <400 µmol/l), the potential benefits of using a radiocontrast study to confirm or exclude a treatable life-threatening acute illness likely outweighed the risk of CIN and its associated attributable mortality. For patients with more severe pre-existing renal impairment (plasma creatinine concentration >400 µmol/l) in the presence of hypotension and diabetes mellitus, a much higher pre-test probability of a life-threatening disease would be needed to justify the risks of a radiocontrast study. These findings have some clinical implications and require further discussion.
First, the analysis showed that the potential harm of CIN from a radiocontrast study is justifiable for most critically ill patients who have symptoms and signs of a life-threatening illness, as the pre-test (or pre-radiocontrast study) probability of such illness (>10%), is usually higher than the estimated attributable mortality of CIN (<4% for patients with mild to moderate renal impairment-plasma creatinine concentration <400 µmol/l-regardless of diabetes mellitus or hypotension). Conversely, for patients with severe renal impairment (plasma creatinine concentrations >400 µmol/l), a much higher pre-test probability of a life-threatening illness would be needed (>15%-20%) to justify the risk of a radiocontrast study, especially if (a) patients also have other risk factors for CIN including age >75 years, hypotension requiring vasopressors, diabetes mellitus, and congestive heart failure, or (b) the underlying life-threatening disease may not be readily reversible (e.g. ischaemic bowel disease). In these difficult situations, alternative investigations not requiring radiocontrast may be useful to increase or decrease the pre-test probability of the life-threatening illness (e.g. transoesophageal echocardiography for thoracic aortic dissection, ventilation-perfusion scan or echocardiography for acute pulmonary embolism) before a final decision about whether the associated risk of a radiocontrast study is justifiable. It is also possible that some invasive investigations, including exploratory laparotomy or laparoscopy, may become less risky than a radiocontrast study in patients who are at extreme risk of developing CIN and its complications. Second, the analysis identified the most risky group of critically ill patients who may develop CIN and mortality from a radiocontrast study. This group of critically ill patients is most likely to benefit from any effective prophylactic measures against CIN. Furthermore, this type of critically ill patient is most suitable for research evaluation on preventive measures against CIN as the sample size required to demonstrate a clinically meaningful outcome (e.g. 5%-10% reduction in dialysis and 3%-4% reduction in mortality) will be more achievable than studying patients who are at much lower risk of developing CIN.
Finally, I would like to acknowledge the limitations of this study. Because I used data from the cardiology literature on CIN, this decision analysis has a potential to overestimate the risk of CIN and its attributable mortality in critically ill patients. This is because the doses of radiocontrast needed during complex percutaneous coronary interventions can be much higher than a standard contrast CT scan or angiography for a critically ill patient. Recent evidence suggested that CIN occurs in only about 15% of critically ill patients who have received radiocontrast 15 , an incidence lower than those reported in the cardiology literature 1, 2 . My results would also not be applicable for patients with end-stage or acute renal failure already on dialysis. In addition, hypotension is known to increase the risk of CIN 1 , but its presence also increases the pre-test probability of a life-threatening illness which would increase the yield and possibly benefit of a radiocontrast study. While the benefit of using prophylactic measures against CIN after administering radiocontrast has not been well studied and documented, it is possible that some simple measures, such as aggressive intravenous hydration, possibly with sodium bicarbonate, both immediately before and after radiocontrast exposure may still have some benefit [3] [4] [5] [6] 16, 17 , and thus should be initiated for critically ill patients who are at high risk of developing CIN.
In summary, for most critically ill patients with eCrCl >20 ml/minute (or plasma creatinine concentration <400 µmol/l), the benefit of confirming or excluding a treatable life-threatening acute illness with a radiocontrast study outweighed the risk of CIN and its associated attributable mortality when the pre-test probability of the life-threatening illness was 10% or higher. A higher pre-test probability of a life-threatening disease would be needed for patients with severe renal impairment (plasma creatinine concentration >400 µmol/l) and multiple risk factors for CIN.
